CALTX — Calliditas Therapeutics AB Share News
0.000.00%
Last trade - 00:00HealthcareMid Cap
- SEK11.16bn
- SEK11.37bn
- SEK1.21bn
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations
Brief: Calliditas Therapeutics Q2 Adj Oper Profit At SEK 70.2 Mln
US FDA approves Novartis' kidney disease drug (updated)
US FDA approves Novartis' kidney disease drug
Brief: Calliditas To Recognize Milestone Payment Related To Approval Of Kinpeygo In Q3
Brief: Calliditas Announces Positive Transform Phase 2B Topline Data In Primary Biliary Cholangitis
Brief: Calliditas Announces Positive Transform Phase 2B Topline Data
Brief: Patent Issued For Calliditas Setanaxib In USA
Brief: Calliditas Partner STADA Receives Positive CHMP Opinion Recommending Full Approval For Kinpeygo For Treatment Of Iga Nephropathy
Deals of the day-Mergers and acquisitions
Calliditas jumps after $1.1 bln buyout by Japan's Asahi
Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billion (updated)
Deals of the day-Mergers and acquisitions
Press Digest: Wall Street Journal - May 28
Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billion
Live Markets: Europe set for steady start; M&A eyed